08:00 , Nov 23, 2015 |  BC Week In Review  |  Clinical News

CardioCel regulatory update

Admedus said CardioCel is now approved in Europe for use in the repair and reconstruction of heart valves. The product is also approved to treat congenital heart defects. CardioCel is a cardiovascular scaffold made from...
07:00 , Apr 27, 2015 |  BC Week In Review  |  Clinical News

HSV-2 vaccine: Phase II started

Admedus began a double-blind, placebo-controlled, Australian Phase II trial to evaluate 1,000 ug intradermal HSV-2 vaccine every 4 weeks for 12 weeks followed by a 1,000 ug booster injection at 6 months in 40 HSV-2-infected...
07:00 , Mar 23, 2015 |  BC Week In Review  |  Financial News

Admedus completes placing

Admedus Ltd. (ASX:AHZ), Perth, Australia   Business: Transplant, Infectious   Date completed: 2015-03-18   Type: Placing   Raised: A$12 million ($9.2 million)   Shares: 171.5 million   Price: A$0.07   Shares after offering: 1.6 billion...
07:00 , Mar 23, 2015 |  BC Week In Review  |  Financial News

Admedus proposes rights offering

Admedus Ltd. (ASX:AHZ), Perth, Australia   Business: Transplant, Infectious   Date announced: 2015-03-18   Type: Rights offering   To be raised: Up to A$16.1 million ($12.3 million)   Shares: 230.6 million   Price: A$0.07  ...
08:00 , Nov 3, 2014 |  BC Week In Review  |  Clinical News

CardioCel regulatory update

Health Canada approved Admedus' CardioCel to repair congenital heart deformities and more complex heart defects. CardioCel is a cardiovascular scaffold made from bovine pericardium that uses the company's ADAPT tissue engineering process. CardioCel is available...
07:00 , May 19, 2014 |  BC Week In Review  |  Financial News

Admedus completes private placement

Admedus Ltd. (ASX:AHZ), Perth, Australia   Business: Transplant, Infectious   Date completed: 5/12/14   Type: Private placement   Raised: A$8 million ($7.5 million)   Shares: 80 million   Price: A$0.10   Shares after offering: 1.3...
08:00 , Feb 24, 2014 |  BC Week In Review  |  Clinical News

CardioCel patch regulatory update

FDA granted 510(k) clearance for Admedus' CardioCel patch for pericardial closure and repair of cardiac and vascular defects. The implantable tissue patch made from bovine pericardium using the company's ADAPT Tissue Engineering Process has CE...
08:00 , Feb 17, 2014 |  BC Week In Review  |  Clinical News

HSV-2 vaccine: Interim Phase I data

Interim data from a Phase I trial showed that Admedus' HSV-2 vaccine was safe and generated a T cell response. The company declined to disclose details or next steps. Admedus Ltd. (ASX:AHZ), Perth, Australia  ...
07:00 , Apr 15, 2013 |  BC Week In Review  |  Clinical News

CardioCel patch: Pilot trial started

Allied Healthcare said investigators began an Australian pilot trial to evaluate CardioCel patch in up to 40 patients ages 1-12 years. The company said it expects a decision by mid-year on CE Mark of CardioCel....
08:00 , Dec 24, 2012 |  BC Week In Review  |  Financial News

Allied Healthcare completes private placement

Allied Healthcare Group Ltd. (ASX:AHZ), Perth, Australia   Business: Transplant, Supply/Service   Date completed: 12/17/12   Type: Private placement   Raised: A$1.7 million ($1.8 million)   Shares: 85 million   Price: A$0.02   Shares after...